Published on August 25, 2009 at 7:57 AM
PuriCore (LSE: PURI), the life sciences company focused on developing and commercializing proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment, today announces its interim results for the six months ending June 30, 2009. An H1 2009 Operating and Financial Report and detailed financial results are available here at PuriCore’s website.
Financial Highlights (unaudited)
- H1 sales of $19.1 million, a decrease of 2% (an increase of 8% on a constant currency basis) (H1 2008: $19.5 million)
- Food Safety sales of $12.6 million, an increase of 17% (H1 2008: $10.8 million)
- Endoscopy sales of $6.1 million, a decrease of 27% (a decrease of 3% on a constant currency basis) (H1 2008: $8.4 million)
- Operating expense reductions of 14% (12% net of non-cash share compensation, depreciation, and amortisation) compared with H1 2008
- $15.8 million in cash as of June 30, 2009 (increased from the cash balance as of March 31, 2009, of $15.6 million as a result of improved working capital and foreign currency)
- Q2 operational cash flow positive
- H1 operational cash outflow of $2.5 million (H1 2008: $4.7 million)
- Debt reduced by $2.7 million in H1 ($1.3 million in Q2)
http://www.puricore.com